Metabolic Syndrome

📋 Key Information Summary

📋

Metabolic syndrome (MetS) is a clustering of central obesity, hypertension, dyslipidaemia, and hyperglycaemia that synergistically amplifies cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) risk.
Prevalence in Australia is approximately 30–35% of adults aged ≥25 years; higher in rural, socioeconomically disadvantaged, and Aboriginal and Torres Strait Islander populations.
Diagnosis requires ≥3 of 5 criteria using the harmonised definition (IDF/AHA/NHLBI 2009): waist circumference, triglycerides, HDL-C, blood pressure, and fasting glucose.
Central insulin resistance with compensatory hyperinsulinaemia is the principal pathophysiological driver, linking all five components.
MetS doubles the risk of CVD events and increases T2DM risk five-fold within 5–10 years.
Waist circumference thresholds differ by ethnicity; for Australian adults, ≥94 cm (men) and ≥80 cm (women) are recommended.
Lifestyle intervention — structured diet, ≥150 min/week moderate-intensity exercise, and 5–7% weight loss — is the cornerstone first-line therapy.
Pharmacotherapy targets individual components: metformin for glycaemic control and modest weight reduction; statins for atherogenic dyslipidaemia; antihypertensives (ACE inhibitors or ARBs preferred) for blood pressure.
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors offer metabolic, cardiovascular, and renal benefits beyond glycaemic control and are increasingly used early.
Bariatric surgery should be considered for BMI ≥40 kg/m² or ≥35 kg/m² with metabolic comorbidities when lifestyle and pharmacotherapy are insufficient.
Assessment must include fasting lipogram, fasting glucose or HbA1c, liver function (NAFLD screening), urine albumin-to-creatinine ratio, and Framingham or QRISK cardiovascular risk score.
Annual monitoring of metabolic parameters, weight, blood pressure, and renal function is essential; more frequent review if on pharmacotherapy.
Aboriginal and Torres Strait Islander peoples experience MetS at younger ages and higher rates; culturally safe, community-led programmes improve engagement and outcomes.

🎧 Audio Brief

How Visceral Fat Drives Metabolic Syndrome

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Metabolic syndrome (MetS) describes a constellation of interrelated metabolic risk factors — central obesity, elevated blood pressure, atherogenic dyslipidaemia (raised triglycerides and low HDL-cholesterol), and impaired fasting glucose — that, when co-existing, confer substantially greater cardiovascular and type 2 diabetes mellitus (T2DM) risk than any single component alone. The concept emerged from early observations by Reaven (1988) linking insulin resistance to hypertension and dyslipidaemia, subsequently codified by the World Health Organization (1998), the European Group for the Study of Insulin Resistance (EGIR, 1999), the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III, 2001), and most recently the harmonised Joint Interim Statement (IDF/AHA/NHLBI, 2009).

In Australia, the AusDiab study (Dunstan et al., 2001) and the more recent Australian Bureau of Statistics National Health Survey (2017–18) indicate that approximately one in three adults aged ≥25 years meets criteria for MetS. Prevalence increases markedly with age, reaching over 50% in those aged ≥65 years. Men tend to present earlier (45–54 years) while women's prevalence rises sharply post-menopause. Socioeconomic gradients are pronounced: rates are highest in the most disadvantaged quintiles and in regional and remote areas.

⚠️

Aboriginal and Torres Strait Islander populations experience MetS prevalence of 30–50%, with onset at significantly younger ages. Cardiovascular mortality in Indigenous Australians is 1.7× that of non-Indigenous Australians (AIHW, 2023), making early identification and culturally appropriate management essential.

The economic burden is substantial: MetS-related hospitalisations, medications, and lost productivity cost the Australian healthcare system an estimated AUD $3.2 billion annually (Deloitte Access Economics, 2019). Importantly, MetS is modifiable — structured lifestyle programmes and targeted pharmacotherapy can reduce CVD events by 20–50% and T2DM incidence by up to 58% (Da Qing, Finnish DPS, DPP trials).

Definition & Diagnostic Criteria

Multiple definitions have been proposed. The harmonised Joint Interim Statement (2009) is recommended for Australian practice as it retains ethnic-specific waist-circumference thresholds while standardising the remaining four criteria.

Criterion	Threshold	Notes
Waist circumference	Men ≥94 cm; Women ≥80 cm (Caucasian/European ethnicity)	Lower thresholds for South Asian, Chinese, Japanese populations. Performed at the midpoint between the iliac crest and lowest rib, at end-expiration.
Triglycerides	≥1.7 mmol/L (or on treatment)	Fasting sample preferred; non-fasting ≥2.0 mmol/L is increasingly accepted.
HDL-cholesterol	Men <1.0 mmol/L; Women <1.3 mmol/L (or on treatment)	Low HDL-C is a strong independent predictor of atherogenic risk.
Blood pressure	Systolic ≥130 mmHg and/or diastolic ≥85 mmHg (or on antihypertensive Rx)	Confirm with ≥2 readings on ≥2 occasions; ambulatory BP monitoring if white-coat suspected.
Fasting glucose	≥5.6 mmol/L (or on treatment for elevated glucose)	HbA1c ≥5.5% (38 mmol/mol) may identify additional at-risk individuals.

Diagnosis requires ≥3 of these 5 criteria. A single fasting blood test (glucose, lipogram) plus clinical assessment (waist circumference, blood pressure) is usually sufficient. The MBS item 66832 (fasting lipogram) and 66841 (fasting glucose/HbA1c) are routinely used in Australian general practice.

🚨

Important: MetS is a risk stratification tool, not a disease per se. Each component must be managed on its own merits as well as collectively. Do not use MetS diagnosis to defer treatment of individual risk factors — treat hypertension, dyslipidaemia, and hyperglycaemia according to their own guidelines regardless of whether three criteria are met.

Pathophysiology (Insulin Resistance)

Central (visceral) adiposity is the primary driver. Excess visceral fat undergoes lipolysis, releasing free fatty acids (FFAs) into the portal circulation. FFAs impair hepatic insulin signalling, promote hepatic gluconeogenesis and VLDL-triglyceride synthesis, and induce hepatic steatosis. Simultaneously, adipose tissue secretes an altered adipokine profile:

↑ Pro-inflammatory cytokines — TNF-α, IL-6, MCP-1 → chronic low-grade inflammation, endothelial dysfunction, and further insulin resistance.
↓ Adiponectin — reduced insulin-sensitising, anti-atherogenic, and anti-inflammatory effects.
↑ Resistin, retinol-binding protein 4 — additional mediators of insulin resistance.

Compensatory hyperinsulinaemia maintains euglycaemia initially but promotes: (1) renal sodium retention → hypertension; (2) hepatic lipogenesis → elevated triglycerides and small dense LDL; (3) suppression of lipoprotein lipase → low HDL-C; and (4) ovarian theca-cell androgen production → PCOS in women.

Over time, pancreatic β-cell exhaustion occurs, transitioning from impaired fasting glucose (IFG) through impaired glucose tolerance (IGT) to overt T2DM. The microbiome, epigenetic factors, sleep apnoea, physical inactivity, and genetic susceptibility (e.g., TCF7L2, FTO polymorphisms) modulate individual risk.

Stage 1

Compensated Insulin Resistance

Hyperinsulinaemia with normal glucose. Central obesity. Mildly elevated triglycerides.

Setting: Primary care — lifestyle intervention

Stage 2

Dysmetabolic State

IFG/IGT. NAFLD. Hypertension. Multiple MetS criteria met.

Setting: Primary care — add pharmacotherapy

Stage 3

End-Organ Disease

T2DM, established CVD, CKD, NASH with fibrosis. β-cell failure.

Setting: Multidisciplinary specialist care

Clinical Implications & Cardiovascular Risk

MetS is independently associated with a 2–3-fold increased risk of cardiovascular events (myocardial infarction, stroke, cardiovascular death) and approximately 5-fold increased risk of developing T2DM (Ford et al., 2008; Mottillo et al., 2010). The relationship is continuous — even 1–2 components confer elevated risk, and the increment per additional component is non-linear.

Outcome	Relative Risk (MetS vs. no MetS)	Population Attributable Fraction
CVD events (MI, stroke)	RR 2.0 (95% CI 1.5–2.7)	~12% of CVD attributable to MetS
Type 2 diabetes	RR 5.0 (95% CI 3.6–7.1)	~40% of T2DM cases preceded by MetS
NAFLD / NASH	RR 3.5 (95% CI 2.6–4.7)	>60% of MetS patients have NAFLD
CKD (eGFR <60 mL/min/1.73 m²)	RR 2.1 (95% CI 1.7–2.6)	Dose-response with number of components
Obstructive sleep apnoea	RR 2.8 (95% CI 2.1–3.7)	Bidirectional relationship with insulin resistance

In Australian practice, use the Framingham Risk Score or Australian Absolute CVD Risk Calculator (NVDPA) to quantify 5-year and 10-year CVD risk. MetS should lower the threshold for initiating lipid-lowering and antihypertensive therapy. The RACGP Red Book recommends CVD risk assessment for all adults aged 45–74 years (35 years for Aboriginal and Torres Strait Islander peoples).

Management

Lifestyle Intervention (First-Line)

Structured lifestyle modification remains the most effective strategy, with NNT of 6.4 to prevent one case of T2DM over 3 years (Diabetes Prevention Programme). Components include:

Weight loss: Target 5–10% of baseline body weight over 6–12 months. Even 3% loss significantly improves triglycerides and insulin sensitivity.
Dietary pattern: Mediterranean-style or DASH diet preferred. Emphasise vegetables, fruits, wholegrains, legumes, nuts, olive oil, fish; reduce saturated fat (<10% energy), refined carbohydrates, sugary drinks, and excess alcohol (<10 standard drinks/week for women, <14 for men per NHMRC guidelines).
Physical activity: ≥150 min/week moderate-intensity (brisk walking, cycling) or ≥75 min/week vigorous-intensity. Add resistance training ≥2 days/week.
Behavioural support: Referral to dietitian (MBS 10954 — GPMP dietitian referral, up to 5 visits/year). Structured programmes such as Life! (Victoria) or My Health for Life (Queensland) are evidence-based.
Smoking cessation: All patients who smoke should receive brief intervention and offer of NRT, varenicline, or bupropion.

Pharmacotherapy by Component

1. Hyperglycaemia / Insulin Resistance

💊

Metformin

Diabex® · Diaformin® · Generic · Biguanide

Adult dose 500 mg PO BD with meals, titrate to 1 g BD over 2–4 weeks

Paediatric dose ≥10 years: 500 mg PO OD–BD, max 2 g/day

Renal adjustment eGFR 30–45: max 500 mg BD; <30: contraindicated

Hepatic adjustment Avoid in significant hepatic impairment (risk of lactic acidosis)

PBS status ✔ PBS General Benefit

💊

Semaglutide (GLP-1 RA)

Ozempic® (injection) · Rybelsus® (oral) · GLP-1 receptor agonist

Adult dose SC: 0.25 mg weekly ×4 wks → 0.5 mg weekly ×4 wks → 1 mg weekly (max 2 mg). PO: 3 mg OD ×30 days → 7 mg OD → 14 mg OD.

CV/weight benefit Mean weight loss 5–15%. Demonstrated MACE reduction (SUSTAIN-6, SELECT).

Renal adjustment eGFR ≥15: no adjustment. <15: limited data, use with caution.

PBS status ⚠ PBS Authority Required (T2DM, inadequate control on metformin + sulfonylurea)

💊

Empagliflozin (SGLT2i)

Jardiance® · SGLT2 inhibitor

Adult dose 10 mg PO OD (may increase to 25 mg OD)

CV/renal benefit MACE reduction (EMPA-REG OUTCOME). Slows CKD progression.

Renal adjustment eGFR ≥20 for CKD benefit. <20: discontinue for glycaemic effect; may continue for cardiorenal benefit to eGFR ≥10.

PBS status ⚠ PBS Authority Required (T2DM or CKD)

2. Dyslipidaemia

💊

Atorvastatin

Lipitor® · Generic · HMG-CoA reductase inhibitor

Adult dose 10–80 mg PO daily (evening preferred but not essential)

Notes First-line statin. High-intensity (40–80 mg) if ≥10% 5-yr CVD risk or established CVD.

PBS status ✔ PBS General Benefit

💊

Ezetimibe

Ezetrol® · Generic · Cholesterol absorption inhibitor

Adult dose 10 mg PO daily, as add-on to statin or as monotherapy if statin intolerant

PBS status ✔ PBS General Benefit

3. Hypertension

Target <130/80 mmHg for patients with MetS and elevated CVD risk or diabetes (2016 Heart Foundation Guideline). For uncomplicated MetS: <140/90 mmHg.

💊

Perindopril

Coversyl® · Generic · ACE inhibitor

Adult dose 5 mg PO OD, titrate to 10 mg OD

Preferred in MetS with diabetes, CKD, or albuminuria. Nephroprotective.

PBS status ✔ PBS General Benefit

💊

Telmisartan

Micardis® · Generic · ARB

Adult dose 40 mg PO OD, titrate to 80 mg OD

Preferred in ACE inhibitor-intolerant patients. Some evidence of PPAR-γ agonism (metabolic benefit).

PBS status ✔ PBS General Benefit

Bariatric / Metabolic Surgery

Consider referral for bariatric surgery in patients with BMI ≥40 kg/m² or ≥35 kg/m² with MetS-related comorbidities (T2DM, obstructive sleep apnoea) who have not achieved adequate metabolic control with lifestyle and pharmacotherapy. Sleeve gastrectomy and Roux-en-Y gastric bypass both achieve 25–35% total body weight loss with durable MetS remission rates of 60–80% at 5 years. Assess suitability via a multidisciplinary metabolic clinic; waitlists are significant in the public system.

Monitoring & Follow-Up

Baseline

Weight, waist circumference, BP, fasting lipogram, fasting glucose / HbA1c, LFTs (NAFLD screening), UACR, eGFR, 12-lead ECG. Calculate absolute CVD risk.

3 months

Review lifestyle goals. Check BP, weight. If on metformin, check eGFR and consider titration.

6 months

Repeat fasting lipogram and HbA1c. Assess statin response (target LDL-C reduction ≥50% or LDL <1.8 mmol/L if high risk). Referral to dietitian if not yet done.

12 months (annual)

Comprehensive review: all baseline parameters. Recalculate CVD risk. Screen for NAFLD (FIB-4 index if indicated). Review medications. Psychological well-being check.

Investigations

Essential

Fasting lipogram (total cholesterol, LDL-C, HDL-C, triglycerides)

MBS 66832. Fasting ≥10 hours. Include non-HDL-C calculation.

Essential

Fasting plasma glucose & HbA1c

MBS 66841 (glucose), 66840 (HbA1c). OGTT if discordance.

Essential

Waist circumference & BMI

Measured at midpoint between iliac crest and lowest rib. Use culturally appropriate thresholds.

Essential

Blood pressure (office ± ambulatory)

≥2 readings on ≥2 occasions. ABPM if white-coat or masked hypertension suspected.

Available

Liver function tests (LFTs)

MBS 66551. ALT, AST, GGT — screen for NAFLD/NASH. FIB-4 index: (age × AST) / (platelets × √ALT).

Available

Urine albumin-to-creatinine ratio (UACR)

MBS 66882. First morning void. Screen for microalbuminuria.

Available

eGFR (CKD-EPI)

MBS 66551. Renal risk stratification.

Available

12-lead ECG

MBS 11707. Baseline cardiac assessment; look for LVH, ischaemic changes.

Referral

Coronary artery calcium (CAC) score

Consider if intermediate CVD risk (5–15% 5-year) to reclassify risk. Not MBS-listed; out-of-pocket ~$200–$300.

Referral

Polysomnography (sleep study)

MBS 12203/12205. If Epworth Sleepiness Scale ≥10 or clinical suspicion of OSA (snoring, witnessed apnoeas).

Special Populations

🤰 Pregnancy

Metformin: Continue if already on — safe in pregnancy (Category A). Used in GDM.

Statins: Contraindicated — discontinue pre-conception or on confirmation of pregnancy.

ACE inhibitors / ARBs: Contraindicated — teratogenic. Switch to labetalol, methyldopa, or nifedipine.

GLP-1 RA / SGLT2i: Discontinue at least 2 months pre-conception. Limited safety data.

Screen for GDM at 24–28 weeks (or earlier if high risk). Weight management via healthy eating and moderate exercise. Monitor for pre-eclampsia.

👶 Paediatrics / Adolescents

Paediatric MetS is not universally defined; the IDF (2007) provides age-stratified criteria (10–16 yrs: obesity + ≥2 others; ≥16 yrs: adult criteria).

Prevalence in Australian adolescents: ~5–8% overall, up to 25% in obese adolescents.

Metformin: Approved ≥10 years. 500 mg OD → BD. Adjunct to lifestyle for obese adolescents with insulin resistance.

Statins: Familial hypercholesterolaemia only (from age 8–10 years with specialist supervision).

Prioritise family-based lifestyle programmes. Screen for T2DM in at-risk adolescents (obese + FHx). Refer to paediatric endocrinologist if refractory.

👴 Elderly (≥65 years)

MetS prevalence >50% in this age group. Frailty assessment essential before aggressive targets.

HbA1c target may be relaxed to ≤58 mmol/mol (7.5%) if frail, limited life expectancy, or hypoglycaemia risk.

Blood pressure target: <140/90 mmHg generally; avoid excessive lowering (fall risk, orthostatic hypotension).

Metformin: Safe with eGFR ≥30. Monitor B12 annually.

Polypharmacy review. Avoid TZDs (fluid retention, fracture risk). Simplify regimens where possible.

🫘 Renal Impairment

MetS accelerates CKD progression via glomerular hyperfiltration, RAAS activation, and inflammation.

Metformin: eGFR 30–45: max 500 mg BD. <30: cease. Monitor eGFR 3–6 monthly.

SGLT2i: Continue to eGFR ≥10 for cardiorenal benefit (per KDIGO 2024).

Statins: No dose adjustment needed; monitor for myopathy if eGFR <30.

Refer to nephrologist if eGFR <30 or progressive decline. Tight BP control (target <130/80) with RAAS blockade.

🫁 Hepatic Impairment / NAFLD

>60% of MetS patients have NAFLD; progression to NASH/cirrhosis warrants screening.

FIB-4 index (age × AST / [platelets × √ALT]) stratifies fibrosis risk. <1.3: low risk; >2.67: high risk — refer hepatologist.

Pioglitazone: Consider in biopsy-proven NASH (off-label in Australia). Liver function monitoring required. Weight gain and fluid retention are limitations.

Metformin: Avoid in Child-Pugh C cirrhosis (lactic acidosis risk). Safe in NAFLD/NASH without cirrhosis.

Weight loss (≥7–10%) is the most effective NASH treatment. Alcohol cessation. Screen for HCC if cirrhosis develops.

🛡️ Immunocompromised

Patients on immunosuppression (transplant recipients, autoimmune disease) have accelerated MetS — corticosteroids, calcineurin inhibitors, and mTOR inhibitors each promote insulin resistance, dyslipidaemia, and hypertension.

Minimise corticosteroid dose where possible. Consider steroid-sparing agents.

Metformin: Safe in immunocompromised patients. May attenuate steroid-induced hyperglycaemia.

Drug interactions: statins with cyclosporine (↑ statin levels, limit simvastatin/atorvastatin dose). Coordinate with transplant/endocrine teams.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiology

MetS prevalence in Aboriginal and Torres Strait Islander adults is estimated at 30–50% — significantly higher than the non-Indigenous population and presenting approximately 10–15 years earlier. The AusDiab and AATSIHS data show waist circumference and fasting glucose are the most commonly abnormal components. T2DM prevalence is 3–4× higher (AIHW, 2023).

Cardiovascular impact

CVD mortality in Aboriginal and Torres Strait Islander peoples is 1.7× that of non-Indigenous Australians, with a widening gap in the 35–54 year age group. MetS contributes to this disparity through earlier onset and compounding social determinants (poverty, food insecurity, housing).

Screening thresholds

CVD risk assessment should commence at age 35 years (vs. 45 for non-Indigenous) per RACGP Red Book. Waist circumference thresholds remain ≥94 cm (men) and ≥80 cm (women) but culturally appropriate measurement practices should be used. Point-of-care HbA1c testing (available via RFDS and ACCHS) overcomes laboratory access barriers in remote communities.

Remote & rural access

Specialist endocrinology, dietitian, and exercise physiology services are limited in remote Australia. Telehealth (MBS 91822 — specialist video consultation) is critical. Aboriginal Community Controlled Health Services (ACCHS) provide holistic, culturally safe care and should be the preferred point of engagement. Remote Area Health Corps and RFDS support GP locum placements.

Culturally safe management

Engagement with community Elders and Aboriginal Health Workers (AHWs) improves programme uptake. Yarning-based consultations, family-inclusive care, and use of Aboriginal interpreters (where language barriers exist) are essential. Lifestyle programmes should incorporate traditional foods, land-based activities, and community gathering (e.g., Deadly Choices, Tackling Indigenous Diabetes).

Food security & exercise

Remote community stores often have limited fresh produce availability and higher costs. Advocacy for community store nutrition policies (NT Healthy Stores 2020 strategy) is important. Group physical activity programmes (e.g., community walking groups, AFL/marngrook) improve engagement. Home-based telehealth exercise programmes are emerging.

Pharmacotherapy considerations

PBS co-payments are lower for Aboriginal and Torres Strait Islander patients holding a Centrelink Health Care Card ($7.30 vs. $31.60 general, 2024). Closing the Gap PBS Co-payment program provides further relief — ensure patients are registered. Medication adherence may be challenged by supply chain disruptions in remote areas; use longer scripts and blister packs where possible.

National programmes

Refer to: Aboriginal and Torres Strait Islander Health Checks (MBS 715) — annual comprehensive health assessment including metabolic screening. National Aboriginal Community Controlled Health Organisation (NACCHO) clinical guidelines. RHDAustralia resources for rheumatic heart disease screening in MetS context. Kidney Health Australia — ATSI-specific CKD screening pathways.

📚 References

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
2. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25(5):829-834.
3. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31(9):1898-1904.
4. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-1132.
5. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2023 summary report. Canberra: AIHW; 2023.
6. National Vascular Disease Prevention Alliance (NVDPA). Absolute cardiovascular disease risk calculator. 2024. Available at: www.cvdcheck.org.au.
7. The Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 10th ed. East Melbourne: RACGP; 2024.
8. Heart Foundation of Australia. Australian guideline for the diagnosis and management of hypertension in adults. Melbourne: National Heart Foundation of Australia; 2016.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117-2128.
10. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
11. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2024;390(24):2221-2232.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
13. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
14. National Aboriginal Community Controlled Health Organisation (NACCHO). Framework for the delivery of Aboriginal and Torres Strait Islander primary health care services. Canberra: NACCHO; 2023.